ArticleMuscle & nerve2017
Validity of the 6 minute walk test in facioscapulohumeral muscular dystrophy.
Article in Muscle & nerve, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 3 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Walking test outcomes in adults with genetic neuromuscular diseases: a systematic literature review of their measurement properties.European journal of physical and rehabilitation medicine · 2024Pooled it
- Measuring the effects of exercise in neuromuscular disorders: a systematic review and meta-analyses.Wellcome open research · 2020Pooled it
- Effect of Muscular Exercise on Patients With Muscular Dystrophy: A Systematic Review and Meta-Analysis of the Literature.Frontiers in neurology · 2020Pooled it
- Effect of creatine monohydrate on motor function in children with facioscapulohumeral muscular dystrophy: A multicenter, randomized, double-blind placebo-controlled crossover trial.Pharmacotherapy · 2025Trial
- Comparison between a novel helical and a posterior ankle-foot orthosis on gait in people with unilateral foot drop: a randomised crossover trial.Journal of neuroengineering and rehabilitation · 2023Trial
- Randomized phase 2 study of ACE-083, a muscle-promoting agent, in facioscapulohumeral muscular dystrophy.Muscle & nerve · 2022Trial
- Allogeneic Human Mesenchymal Stem Cell Infusions for Aging Frailty.The journals of gerontology. Series A, Biological sciences and medical sciences · 2017Trial
- High-intensity interval training in facioscapulohumeral muscular dystrophy type 1: a randomized clinical trial.Journal of neurology · 2017Trial
- Six-minute walk test to assess muscular fatigability and mobility in children with congenital myasthenic syndrome: a pilot study.Revista da Associacao Medica Brasileira (1992) · 2026Article
- French National Protocol for diagnosis and care of facioscapulohumeral muscular dystrophy (FSHD).Journal of neurology · 2024Review
- Defining clinical endpoints in limb girdle muscular dystrophy: a GRASP-LGMD study.BMC neurology · 2024Article
- Defining Clinical Endpoints in Limb Girdle Muscular Dystrophy: A GRASP-LGMD study.Research square · 2023Article
- Associations between lower extremity muscle fat fraction and motor performance in myotonic dystrophy type 2: A pilot study.Muscle & nerve · 2023Article
- Dynamic magnetic resonance imaging of muscle contraction in facioscapulohumeral muscular dystrophy.Scientific reports · 2022Article
- Spatio-temporal gait differences in facioscapulohumeral muscular dystrophy during single and dual task overground walking - A pilot study.Journal of clinical and translational research · 2022Article
- Review
- Temporal trends in 6-minute walking distance for older Japanese adults between 1998 and 2017.Journal of sport and health science · 2021Article
- Walking and weakness in children: a narrative review of gait and functional ambulation in paediatric neuromuscular disease.Journal of foot and ankle research · 2020Review
- Validation of Motor Outcome Measures in Myotonic Dystrophy Type 2.Frontiers in neurology · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
Abstract
introductionIn preparation for future clinical trials, we determined the reliability, relationship to measures of disease severity, and consistency across sites of the 6 Minute Walk Test (6MWT) in patients with facioscapulohumeral muscular dystrophy (FSHD).
methodsGenetically defined and clinically affected FSHD participants at 2 sites performed the 6MWT, the Timed Up and Go, and the 30 foot Go/Timed 10 meter test as measures of mobility using standard procedures.
resultsEight-six participants representing the full range of severity performed the 6MWT. The mean 6MWT distance was 404.3 meters (SD 123.9), with no difference between sites. The 6MWT was reliable (n = 25; intraclass correlation coefficient = 0.99) and demonstrated moderate to strong correlations with lower extremity strength, functional outcomes, and FSHD Clinical Score.
conclusionsThe 6MWT is reliable and is associated with other measures of FSHD disease severity. Future directions include assessing its sensitivity to disease progression. Muscle Nerve 55: 333-337, 2017.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.